Imaging response assessment with post 177Lu-PSMA-617 therapy SPECT-CT in metastatic castrate resistant prostate cancer: Adding value with a technologist driven postprocessing workflow

被引：0
|
作者：
Messmer, Jaylee [1 ]
Soehl, Kaleb [2 ]
Burkett, Brian [3 ]
Kendi, Ayse [3 ]
Johnson, Geoffrey [3 ]
Childs, Daniel [3 ]
Abdelrazek, Ahmad [3 ]
Mahmoud, Ahmed [3 ]
Pessoa, Rodrigo Rodrigues [3 ]
Nabavizadeh, Reza [3 ]
Kwon, Eugene [3 ]
Matthew, Patrick Navin [3 ]
Thorpe, Matthew [3 ]
机构：
[1] Mayo Clin, Sch Hlth Sci, Rochester, MN USA
[2] Mayo Clin, Nucl Med Technol Program Minnesota, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
TS16
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Kambiz Rahbar
    Martin Bögeman
    Anna Yordanova
    Maria Eveslage
    Michael Schäfers
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 243 - 246
  • [22] Liquid biopsy biomarker analysis during treatment with 177Lu-PSMA-617 in castrate resistant prostate cancer
    Sperger, Jamie M.
    Sharifi, Marina N.
    Nunamaker, Luke
    Carreno, Viridiana
    Chang, Alex H.
    Reese, Shannon R.
    Linebarger, Charlotte
    Taylor, Amy K.
    Bliitzer, Grace C.
    Floberg, John
    Zhao, Shuang G.
    Lang, Joshua M.
    CANCER RESEARCH, 2024, 84 (06)
  • [23] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [24] Whole-Body Dosimetry in Therapy of Metastatic Prostate Cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Groener, D.
    Bockisch, B.
    Mader, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S695 - S695
  • [25] Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis
    Kim, Yong Joong
    Kim, Yong-il
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (10) : 728 - 734
  • [26] Fractionated 177Lu-PSMA-617 therapy with 101 GBq in a patient with metastatic prostate cancer
    Happel, C.
    Wichert, J.
    Kranert, W. T.
    Voeller, L.
    Bockisch, B.
    Groener, D.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S697 - S697
  • [27] Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
    Schlenkhoff, Carl Diedrich
    Knuepfer, Eberhard
    Essler, Markus
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 572 - 573
  • [28] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Heinzel, Alexander
    Boghos, Dima
    Mottaghy, Felix M.
    Gaertner, Florian
    Essler, Markus
    von Mallek, Dirk
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1054 - 1062
  • [29] Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy
    Boughdad, Sarah
    Meyer, Marie
    Da Mota, Michael
    Allenbach, Gilles
    Nicod-Lalonde, Marie
    Prior, John
    Schaefer, Niklaus
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [30] RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
    Calais, Jeremie
    Fendler, Wolfgang P.
    Eiber, Matthias
    Lassmann, MIchael
    Dahlbom, Magnus
    Esfandiari, Rouzbeh
    Gartmann, Jeannine
    Nguyen, Kathleen
    Pan Thin
    Lok, Vincent
    Herrmann, Ken
    Czernin, Johannes
    Delpassand, Ebrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345